These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 11948140)

  • 1. Luteinizing hormone-releasing hormone agonist limits DU-145 prostate cancer growth by attenuating epidermal growth factor receptor signaling.
    Wells A; Souto JC; Solava J; Kassis J; Bailey KJ; Turner T
    Clin Cancer Res; 2002 Apr; 8(4):1251-7. PubMed ID: 11948140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiproliferative effects of luteinizing hormone-releasing hormone (LHRH) agonists on human androgen-independent prostate cancer cell line DU 145: evidence for an autocrine-inhibitory LHRH loop.
    Dondi D; Limonta P; Moretti RM; Marelli MM; Garattini E; Motta M
    Cancer Res; 1994 Aug; 54(15):4091-5. PubMed ID: 8033142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers.
    Letsch M; Schally AV; Szepeshazi K; Halmos G; Nagy A
    Clin Cancer Res; 2003 Oct; 9(12):4505-13. PubMed ID: 14555524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DU145 human prostate carcinoma invasiveness is modulated by urokinase receptor (uPAR) downstream of epidermal growth factor receptor (EGFR) signaling.
    Mamoune A; Kassis J; Kharait S; Kloeker S; Manos E; Jones DA; Wells A
    Exp Cell Res; 2004 Sep; 299(1):91-100. PubMed ID: 15302576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A role for phospholipase C-gamma-mediated signaling in tumor cell invasion.
    Kassis J; Moellinger J; Lo H; Greenberg NM; Kim HG; Wells A
    Clin Cancer Res; 1999 Aug; 5(8):2251-60. PubMed ID: 10473113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Melatonin and prostate cancer cell proliferation: interplay with castration, epidermal growth factor, and androgen sensitivity.
    Siu SW; Lau KW; Tam PC; Shiu SY
    Prostate; 2002 Jul; 52(2):106-22. PubMed ID: 12111702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of epidermal growth factor receptor signaling by Saussurea involucrata, a rare traditional Chinese medicinal herb, in human hormone-resistant prostate cancer PC-3 cells.
    Way TD; Lee JC; Kuo DH; Fan LL; Huang CH; Lin HY; Shieh PC; Kuo PT; Liao CF; Liu H; Kao JY
    J Agric Food Chem; 2010 Mar; 58(6):3356-65. PubMed ID: 20166659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of LHRH agonists on the growth of human prostatic tumor cells: "in vitro" and "in vivo" studies.
    Montagnani Marelli M; Moretti RM; Dondi D; Limonta P; Motta M
    Arch Ital Urol Androl; 1997 Sep; 69(4):257-63. PubMed ID: 9396187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular inhibition of phospholipase cgamma signaling abrogates DU-145 prostate tumor cell invasion.
    Turner T; Epps-Fung MV; Kassis J; Wells A
    Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2275-82. PubMed ID: 9815625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
    Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
    Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suppression of LNCaP prostate cancer xenograft tumors by a prostate-specific protein tyrosine phosphatase, prostatic acid phosphatase.
    Igawa T; Lin FF; Rao P; Lin MF
    Prostate; 2003 Jun; 55(4):247-58. PubMed ID: 12712404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of human experimental prostate cancers by a targeted cytotoxic luteinizing hormone-releasing hormone analog AN-207.
    Stangelberger A; Schally AV; Nagy A; Szepeshazi K; Kanashiro CA; Halmos G
    Prostate; 2006 Feb; 66(2):200-10. PubMed ID: 16173040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Growth-inhibitory effects of luteinizing hormone-releasing hormone (LHRH) agonists on xenografts of the DU 145 human androgen-independent prostate cancer cell line in nude mice.
    Dondi D; Moretti RM; Montagnani Marelli M; Pratesi G; Polizzi D; Milani M; Motta M; Limonta P
    Int J Cancer; 1998 May; 76(4):506-11. PubMed ID: 9590126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Androgen level variations, clinical response to LHRH agonists and changes in the quality of life subscales in metastatic prostate cancer--speculations about possible role of the monoamine system.
    Popov I; Jelić S; Radosavljević D; Nikolić-Tomasević Z
    Neoplasma; 1997; 44(5):308-13. PubMed ID: 9473791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Luteinizing hormone-releasing hormone agonists interfere with the stimulatory actions of epidermal growth factor in human prostatic cancer cell lines, LNCaP and DU 145.
    Moretti RM; Marelli MM; Dondi D; Poletti A; Martini L; Motta M; Limonta P
    J Clin Endocrinol Metab; 1996 Nov; 81(11):3930-7. PubMed ID: 8923840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ionizing radiation causes a dose-dependent release of transforming growth factor alpha in vitro from irradiated xenografts and during palliative treatment of hormone-refractory prostate carcinoma.
    Hagan M; Yacoub A; Dent P
    Clin Cancer Res; 2004 Sep; 10(17):5724-31. PubMed ID: 15355899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gonadotropin-releasing hormone agonists reduce the migratory and the invasive behavior of androgen-independent prostate cancer cells by interfering with the activity of IGF-I.
    Montagnani Marelli M; Moretti RM; Mai S; Procacci P; Limonta P
    Int J Oncol; 2007 Jan; 30(1):261-71. PubMed ID: 17143537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer.
    Di Lorenzo G; Tortora G; D'Armiento FP; De Rosa G; Staibano S; Autorino R; D'Armiento M; De Laurentiis M; De Placido S; Catalano G; Bianco AR; Ciardiello F
    Clin Cancer Res; 2002 Nov; 8(11):3438-44. PubMed ID: 12429632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of epidermal growth factor receptor activity by two pyrimidopyrimidine derivatives.
    Solca FF; Baum A; Langkopf E; Dahmann G; Heider KH; Himmelsbach F; van Meel JC
    J Pharmacol Exp Ther; 2004 Nov; 311(2):502-9. PubMed ID: 15199094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence that prostate gonadotropin-releasing hormone receptors mediate an anti-tumourigenic response to analogue therapy in hormone refractory prostate cancer.
    Gnanapragasam VJ; Darby S; Khan MM; Lock WG; Robson CN; Leung HY
    J Pathol; 2005 Jun; 206(2):205-13. PubMed ID: 15818594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.